ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Amgen has agreed to buy the antibody maker Teneobio for $900 million upfront and up to $1.6 billion in milestone payments. Teneobio makes bispecific and multispecific antibodies, including a new class called human heavy-chain antibodies that bind to multiple targets on different cell types. Teneobio’s technology will add to Amgen’s BiTE technology for producing T-cell-engaging antibodies. The sale includes Teneobio’s TNB-585, a bispecific antibody in clinical trials for certain treatment-resistant prostate cancers.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter